Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)

Belij-Rammerstorfer, S; Sheehan, E; Li, G; Bibi, S; Wright, D; Voysey, M; Bissett, C; Barman, N; Camara, S; Yong, AA; Costa Clemens, SA; Harris, M; Flaxman, A; Barrett, J; Hussain, K; Lipunga, G; Shaw, RH; Smith, H; Cheruiyot, S; Gitonga, JN; Mugo, D; Karanja, HK; Warimwe, GM; Hamaluba, MM; Weckx, LY; Pollard, AJ; Lambe, T

COVID-19 Collection

Journal article

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222)

Abstract:: Background
ChAdOx1 nCoV-19 (AZD1222) vaccine was widely deployed to protect against severe COVID-19 in adults, but the relationship between pre-existing immunity to human seasonal coronaviruses (HCoVs) and vaccine-induced SARS-CoV-2 (SCoV2) response across age groups remains unclear.
Methods
We analysed SCoV2 and HCoVs antibody profiles in UK volunteers (aged 6-≥70), assessing antibody levels, avidity, and FcγR binding after receiving one or two doses of ChAdOx1 nCoV-19. Adult cohorts from trials in Brazil and Kenya were also included to evaluate geographical impacts on baseline HCoVs and SCoV2 induced response.
Findings
In the UK cohort, younger individuals had higher SCoV2 IgG, avidity, FcγR binding and cross-reactivity, particularly towards OC43 and HKU1. The greatest differences were seen after the first dose of ChAdOx1 nCoV-19, but these effects diminished after the second dose. Although baseline HCoVs IgG varied geographically, similar trends were observed across adult cohorts with younger adults showing higher SCoV2 IgG compared to older adults (UK and Brazil).
Interpretation
These findings contribute to a better understanding of the immunogenicity of ChAdOx1-based vaccines in various age groups. Determining whether this applies across other vaccines using same platform is essential for evaluating the viability of one-dose regimens in outbreak responses.
Funding
The clinical trials COV002, COV003, COV004, and COV006 were made possible by funding from Astra Zeneca, the NIHR and the University of Oxford, UK Department of Health and Social Care, through the UK National Institute for Health and Care Research, the Wellcome Trust (220991), and Innovate UK (project 971614).

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Belij-Rammerstorfer, S., Sheehan, E., Li, G., Bibi, S., Wright, D., Voysey, M., Bissett, C., Barman, N., Camara, S., Yong, A. A., Costa Clemens, S. A., Harris, M., Flaxman, A., Barrett, J., Hussain, K., Lipunga, G., Shaw, R. H., Smith, H., Cheruiyot, S., … Lambe, T. (2025). Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222). EBioMedicine, 118.

MLA Style

Belij-Rammerstorfer, S, et al. “Age Differences in Immunity to Human Seasonal Coronaviruses and the Immunogenicity of ChAdOx1 NCoV-19 (AZD1222).” EBioMedicine, vol. 118, 2025.

Chicago Style

Belij-Rammerstorfer, S, E Sheehan, G Li, et al. 2025. “Age Differences in Immunity to Human Seasonal Coronaviruses and the Immunogenicity of ChAdOx1 NCoV-19 (AZD1222).” EBioMedicine 118.
Print